Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2009-09-29

AUTHORS

A Okines, O del Puerto, D Cunningham, I Chau, E Van Cutsem, L Saltz, J Cassidy

ABSTRACT

Background:Complete resection of metastases can result in cure for selected patients with metastatic colorectal cancer.Methods:First BEAT evaluated the safety of bevacizumab with first-line chemotherapy in 1914 patients. Prospectively collected data from 225 patients who underwent curative-intent surgery were analysed, including an exploratory comparison of resection rate in patients treated with different regimens. NO16966 compared efficacy of oxaliplatin-based chemotherapy plus bevacizumab or placebo in 1400 patients. A retrospective analysis of resection rate was undertaken.Results:In First BEAT, 225 out of 1914 patients (11.8%) underwent curative-intent surgery at median 64 days (range 42–100) after the last dose of bevacizumab. R0 resection was achieved in 173 out of 225 patients (76.9%). There were no surgery-related deaths and serious post-operative complications were uncommon, with grade 3/4 bleeding and wound-healing events reported in 0.4% and 1.8%, respectively. Resection rates were highest in patients receiving oxaliplatin-based combination chemotherapy (P=0.002), possibly confounded by patient selection. In NO16966, 44 out of 699 patients treated with bevacizumab (6.3%) and 34 out of 701 patients treated with placebo (4.9%) underwent R0 metastasectomy (P=0.24).Conclusions:The rate of serious post-operative complications in First BEAT was comparable to historical controls without bevacizumab. In NO16966, there were no statistically significant differences in resection rates or overall survival in patients treated with bevacizumab vs placebo. More... »

PAGES

1033-1038

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/sj.bjc.6605259

DOI

http://dx.doi.org/10.1038/sj.bjc.6605259

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1048476579

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/19789532


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Angiogenesis Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bevacizumab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Colorectal Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Combined Modality Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Metastasis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Postoperative Complications", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Medicine, The Royal Marsden Hospital NHS Foundation Trust, Sutton, Surrey, UK", 
          "id": "http://www.grid.ac/institutes/grid.5072.0", 
          "name": [
            "Department of Medicine, The Royal Marsden Hospital NHS Foundation Trust, Sutton, Surrey, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Okines", 
        "givenName": "A", 
        "id": "sg:person.011120523514.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011120523514.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "F Hoffman La Roche Ltd, Welwyn Garden City, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "F Hoffman La Roche Ltd, Welwyn Garden City, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Puerto", 
        "givenName": "O del", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, The Royal Marsden Hospital NHS Foundation Trust, Sutton, Surrey, UK", 
          "id": "http://www.grid.ac/institutes/grid.5072.0", 
          "name": [
            "Department of Medicine, The Royal Marsden Hospital NHS Foundation Trust, Sutton, Surrey, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cunningham", 
        "givenName": "D", 
        "id": "sg:person.01320161130.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320161130.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, The Royal Marsden Hospital NHS Foundation Trust, Sutton, Surrey, UK", 
          "id": "http://www.grid.ac/institutes/grid.5072.0", 
          "name": [
            "Department of Medicine, The Royal Marsden Hospital NHS Foundation Trust, Sutton, Surrey, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chau", 
        "givenName": "I", 
        "id": "sg:person.01035560774.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01035560774.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Digestive Oncology Unit, University Hospital, Gasthuisberg, Leuven, Belgium", 
          "id": "http://www.grid.ac/institutes/grid.410569.f", 
          "name": [
            "Digestive Oncology Unit, University Hospital, Gasthuisberg, Leuven, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Van Cutsem", 
        "givenName": "E", 
        "id": "sg:person.01214007230.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01214007230.69"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Memorial Sloan Kettering Cancer Center, New York City, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.51462.34", 
          "name": [
            "Memorial Sloan Kettering Cancer Center, New York City, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Saltz", 
        "givenName": "L", 
        "id": "sg:person.011701556564.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011701556564.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cancer Research UK, Glasgow, UK", 
          "id": "http://www.grid.ac/institutes/grid.11485.39", 
          "name": [
            "Cancer Research UK, Glasgow, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cassidy", 
        "givenName": "J", 
        "id": "sg:person.015665060162.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015665060162.24"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00280-007-0588-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029987674", 
          "https://doi.org/10.1007/s00280-007-0588-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6603670", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040702997", 
          "https://doi.org/10.1038/sj.bjc.6603670"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10434-001-0347-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015538540", 
          "https://doi.org/10.1007/s10434-001-0347-3"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2009-09-29", 
    "datePublishedReg": "2009-09-29", 
    "description": "Background:Complete resection of metastases can result in cure for selected patients with metastatic colorectal cancer.Methods:First BEAT evaluated the safety of bevacizumab with first-line chemotherapy in 1914 patients. Prospectively collected data from 225 patients who underwent curative-intent surgery were analysed, including an exploratory comparison of resection rate in patients treated with different regimens. NO16966 compared efficacy of oxaliplatin-based chemotherapy plus bevacizumab or placebo in 1400 patients. A retrospective analysis of resection rate was undertaken.Results:In First BEAT, 225 out of 1914 patients (11.8%) underwent curative-intent surgery at median 64 days (range 42\u2013100) after the last dose of bevacizumab. R0 resection was achieved in 173 out of 225 patients (76.9%). There were no surgery-related deaths and serious post-operative complications were uncommon, with grade 3/4 bleeding and wound-healing events reported in 0.4% and 1.8%, respectively. Resection rates were highest in patients receiving oxaliplatin-based combination chemotherapy (P=0.002), possibly confounded by patient selection. In NO16966, 44 out of 699 patients treated with bevacizumab (6.3%) and 34 out of 701 patients treated with placebo (4.9%) underwent R0 metastasectomy (P=0.24).Conclusions:The rate of serious post-operative complications in First BEAT was comparable to historical controls without bevacizumab. In NO16966, there were no statistically significant differences in resection rates or overall survival in patients treated with bevacizumab vs placebo.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/sj.bjc.6605259", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1017082", 
        "issn": [
          "0007-0920", 
          "1532-1827"
        ], 
        "name": "British Journal of Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "7", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "101"
      }
    ], 
    "keywords": [
      "curative-intent surgery", 
      "serious post-operative complications", 
      "first-line chemotherapy", 
      "post-operative complications", 
      "resection rate", 
      "first beat", 
      "oxaliplatin-based combination chemotherapy", 
      "safety of bevacizumab", 
      "grade 3/4 bleeding", 
      "metastatic colorectal cancer", 
      "oxaliplatin-based chemotherapy", 
      "surgery-related deaths", 
      "NO16966 trial", 
      "last dose", 
      "R0 resection", 
      "overall survival", 
      "complete resection", 
      "combination chemotherapy", 
      "patient selection", 
      "different regimens", 
      "colorectal cancer", 
      "historical controls", 
      "retrospective analysis", 
      "bevacizumab", 
      "patients", 
      "chemotherapy", 
      "NO16966", 
      "placebo", 
      "surgery", 
      "wound-healing events", 
      "resection", 
      "complications", 
      "significant differences", 
      "beats", 
      "metastasectomy", 
      "bleeding", 
      "regimens", 
      "exploratory comparison", 
      "metastasis", 
      "cancer", 
      "dose", 
      "trials", 
      "rate", 
      "efficacy", 
      "death", 
      "cure", 
      "survival", 
      "days", 
      "safety", 
      "differences", 
      "control", 
      "events", 
      "data", 
      "comparison", 
      "analysis", 
      "selection"
    ], 
    "name": "Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial", 
    "pagination": "1033-1038", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1048476579"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/sj.bjc.6605259"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "19789532"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/sj.bjc.6605259", 
      "https://app.dimensions.ai/details/publication/pub.1048476579"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T15:53", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_492.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/sj.bjc.6605259"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605259'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605259'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605259'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605259'


 

This table displays all metadata directly associated to this object as RDF triples.

234 TRIPLES      21 PREDICATES      97 URIs      86 LITERALS      20 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/sj.bjc.6605259 schema:about N09260f07763348d68a07c4d42240c554
2 N1ad09fc9453d4abba25b2350e2bd55c6
3 N26cae269fa72408599670d0a29f980ed
4 N2a51f1364bee473c95bf11d9fd7197a2
5 N35200f974b7c4334a4e246ee21de9aa3
6 N4273a55c15124ac2bd39c20622146b76
7 N49189ebfdf12436a888d5b356372d830
8 N4b8d1b3a52d243c58e89942e36e8eddd
9 N508c57a93f484c4194dac475e2f9ac43
10 N6845efa922d0490fa0e4fc1bc1e95815
11 N8804f0cd88324d2d849b7a416d68d950
12 N931e22592c864755a0ff5c27ec2f7eb5
13 Naa28d50879334b69b447e1c997aa2016
14 anzsrc-for:11
15 anzsrc-for:1112
16 schema:author N15a5e325e05d48d88d41a5b4817a3b09
17 schema:citation sg:pub.10.1007/s00280-007-0588-3
18 sg:pub.10.1007/s10434-001-0347-3
19 sg:pub.10.1038/sj.bjc.6603670
20 schema:datePublished 2009-09-29
21 schema:datePublishedReg 2009-09-29
22 schema:description Background:Complete resection of metastases can result in cure for selected patients with metastatic colorectal cancer.Methods:First BEAT evaluated the safety of bevacizumab with first-line chemotherapy in 1914 patients. Prospectively collected data from 225 patients who underwent curative-intent surgery were analysed, including an exploratory comparison of resection rate in patients treated with different regimens. NO16966 compared efficacy of oxaliplatin-based chemotherapy plus bevacizumab or placebo in 1400 patients. A retrospective analysis of resection rate was undertaken.Results:In First BEAT, 225 out of 1914 patients (11.8%) underwent curative-intent surgery at median 64 days (range 42–100) after the last dose of bevacizumab. R0 resection was achieved in 173 out of 225 patients (76.9%). There were no surgery-related deaths and serious post-operative complications were uncommon, with grade 3/4 bleeding and wound-healing events reported in 0.4% and 1.8%, respectively. Resection rates were highest in patients receiving oxaliplatin-based combination chemotherapy (P=0.002), possibly confounded by patient selection. In NO16966, 44 out of 699 patients treated with bevacizumab (6.3%) and 34 out of 701 patients treated with placebo (4.9%) underwent R0 metastasectomy (P=0.24).Conclusions:The rate of serious post-operative complications in First BEAT was comparable to historical controls without bevacizumab. In NO16966, there were no statistically significant differences in resection rates or overall survival in patients treated with bevacizumab vs placebo.
23 schema:genre article
24 schema:isAccessibleForFree true
25 schema:isPartOf N8ca3561c7a3944acb97d0469ec65d63e
26 Nc9f2dcd23b9f4a9e92be29c8999addaf
27 sg:journal.1017082
28 schema:keywords NO16966
29 NO16966 trial
30 R0 resection
31 analysis
32 beats
33 bevacizumab
34 bleeding
35 cancer
36 chemotherapy
37 colorectal cancer
38 combination chemotherapy
39 comparison
40 complete resection
41 complications
42 control
43 curative-intent surgery
44 cure
45 data
46 days
47 death
48 differences
49 different regimens
50 dose
51 efficacy
52 events
53 exploratory comparison
54 first beat
55 first-line chemotherapy
56 grade 3/4 bleeding
57 historical controls
58 last dose
59 metastasectomy
60 metastasis
61 metastatic colorectal cancer
62 overall survival
63 oxaliplatin-based chemotherapy
64 oxaliplatin-based combination chemotherapy
65 patient selection
66 patients
67 placebo
68 post-operative complications
69 rate
70 regimens
71 resection
72 resection rate
73 retrospective analysis
74 safety
75 safety of bevacizumab
76 selection
77 serious post-operative complications
78 significant differences
79 surgery
80 surgery-related deaths
81 survival
82 trials
83 wound-healing events
84 schema:name Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial
85 schema:pagination 1033-1038
86 schema:productId N3098696bd49a446b8721c948ce3eac9a
87 N444ac815d0884236af4f7cc50c02840b
88 N8328019280514185a8123ee21c1d7aee
89 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048476579
90 https://doi.org/10.1038/sj.bjc.6605259
91 schema:sdDatePublished 2022-09-02T15:53
92 schema:sdLicense https://scigraph.springernature.com/explorer/license/
93 schema:sdPublisher N27570af0aa66489aa553e994814050b8
94 schema:url https://doi.org/10.1038/sj.bjc.6605259
95 sgo:license sg:explorer/license/
96 sgo:sdDataset articles
97 rdf:type schema:ScholarlyArticle
98 N05c006c253ca410e9d8d6630165549be rdf:first sg:person.01214007230.69
99 rdf:rest N5bcf522cbe304cc5ac38e0d106d20893
100 N09260f07763348d68a07c4d42240c554 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Humans
102 rdf:type schema:DefinedTerm
103 N15a5e325e05d48d88d41a5b4817a3b09 rdf:first sg:person.011120523514.08
104 rdf:rest N23138c989a56408087579af75003ab46
105 N1ad09fc9453d4abba25b2350e2bd55c6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Combined Modality Therapy
107 rdf:type schema:DefinedTerm
108 N23138c989a56408087579af75003ab46 rdf:first N7e46c009387c4d44bf93dcf514ec9cc9
109 rdf:rest N74dfb4755d2745b88b2df18e2d3b9984
110 N26cae269fa72408599670d0a29f980ed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Antibodies, Monoclonal
112 rdf:type schema:DefinedTerm
113 N27570af0aa66489aa553e994814050b8 schema:name Springer Nature - SN SciGraph project
114 rdf:type schema:Organization
115 N2a51f1364bee473c95bf11d9fd7197a2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Antineoplastic Combined Chemotherapy Protocols
117 rdf:type schema:DefinedTerm
118 N2f1798630b0b46069fc9ecaddd82d28d rdf:first sg:person.01035560774.45
119 rdf:rest N05c006c253ca410e9d8d6630165549be
120 N3098696bd49a446b8721c948ce3eac9a schema:name doi
121 schema:value 10.1038/sj.bjc.6605259
122 rdf:type schema:PropertyValue
123 N35200f974b7c4334a4e246ee21de9aa3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Male
125 rdf:type schema:DefinedTerm
126 N4273a55c15124ac2bd39c20622146b76 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Antibodies, Monoclonal, Humanized
128 rdf:type schema:DefinedTerm
129 N444ac815d0884236af4f7cc50c02840b schema:name dimensions_id
130 schema:value pub.1048476579
131 rdf:type schema:PropertyValue
132 N49189ebfdf12436a888d5b356372d830 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Bevacizumab
134 rdf:type schema:DefinedTerm
135 N4b8d1b3a52d243c58e89942e36e8eddd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Female
137 rdf:type schema:DefinedTerm
138 N508c57a93f484c4194dac475e2f9ac43 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Neoplasm Metastasis
140 rdf:type schema:DefinedTerm
141 N5bcf522cbe304cc5ac38e0d106d20893 rdf:first sg:person.011701556564.34
142 rdf:rest Nde724c1e7a514c2c96cd7da71ddda90c
143 N6845efa922d0490fa0e4fc1bc1e95815 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Colorectal Neoplasms
145 rdf:type schema:DefinedTerm
146 N74dfb4755d2745b88b2df18e2d3b9984 rdf:first sg:person.01320161130.16
147 rdf:rest N2f1798630b0b46069fc9ecaddd82d28d
148 N7e46c009387c4d44bf93dcf514ec9cc9 schema:affiliation grid-institutes:None
149 schema:familyName Puerto
150 schema:givenName O del
151 rdf:type schema:Person
152 N8328019280514185a8123ee21c1d7aee schema:name pubmed_id
153 schema:value 19789532
154 rdf:type schema:PropertyValue
155 N8804f0cd88324d2d849b7a416d68d950 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Middle Aged
157 rdf:type schema:DefinedTerm
158 N8ca3561c7a3944acb97d0469ec65d63e schema:issueNumber 7
159 rdf:type schema:PublicationIssue
160 N931e22592c864755a0ff5c27ec2f7eb5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Postoperative Complications
162 rdf:type schema:DefinedTerm
163 Naa28d50879334b69b447e1c997aa2016 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Angiogenesis Inhibitors
165 rdf:type schema:DefinedTerm
166 Nc9f2dcd23b9f4a9e92be29c8999addaf schema:volumeNumber 101
167 rdf:type schema:PublicationVolume
168 Nde724c1e7a514c2c96cd7da71ddda90c rdf:first sg:person.015665060162.24
169 rdf:rest rdf:nil
170 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
171 schema:name Medical and Health Sciences
172 rdf:type schema:DefinedTerm
173 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
174 schema:name Oncology and Carcinogenesis
175 rdf:type schema:DefinedTerm
176 sg:journal.1017082 schema:issn 0007-0920
177 1532-1827
178 schema:name British Journal of Cancer
179 schema:publisher Springer Nature
180 rdf:type schema:Periodical
181 sg:person.01035560774.45 schema:affiliation grid-institutes:grid.5072.0
182 schema:familyName Chau
183 schema:givenName I
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01035560774.45
185 rdf:type schema:Person
186 sg:person.011120523514.08 schema:affiliation grid-institutes:grid.5072.0
187 schema:familyName Okines
188 schema:givenName A
189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011120523514.08
190 rdf:type schema:Person
191 sg:person.011701556564.34 schema:affiliation grid-institutes:grid.51462.34
192 schema:familyName Saltz
193 schema:givenName L
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011701556564.34
195 rdf:type schema:Person
196 sg:person.01214007230.69 schema:affiliation grid-institutes:grid.410569.f
197 schema:familyName Van Cutsem
198 schema:givenName E
199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01214007230.69
200 rdf:type schema:Person
201 sg:person.01320161130.16 schema:affiliation grid-institutes:grid.5072.0
202 schema:familyName Cunningham
203 schema:givenName D
204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320161130.16
205 rdf:type schema:Person
206 sg:person.015665060162.24 schema:affiliation grid-institutes:grid.11485.39
207 schema:familyName Cassidy
208 schema:givenName J
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015665060162.24
210 rdf:type schema:Person
211 sg:pub.10.1007/s00280-007-0588-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029987674
212 https://doi.org/10.1007/s00280-007-0588-3
213 rdf:type schema:CreativeWork
214 sg:pub.10.1007/s10434-001-0347-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015538540
215 https://doi.org/10.1007/s10434-001-0347-3
216 rdf:type schema:CreativeWork
217 sg:pub.10.1038/sj.bjc.6603670 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040702997
218 https://doi.org/10.1038/sj.bjc.6603670
219 rdf:type schema:CreativeWork
220 grid-institutes:None schema:alternateName F Hoffman La Roche Ltd, Welwyn Garden City, UK
221 schema:name F Hoffman La Roche Ltd, Welwyn Garden City, UK
222 rdf:type schema:Organization
223 grid-institutes:grid.11485.39 schema:alternateName Cancer Research UK, Glasgow, UK
224 schema:name Cancer Research UK, Glasgow, UK
225 rdf:type schema:Organization
226 grid-institutes:grid.410569.f schema:alternateName Digestive Oncology Unit, University Hospital, Gasthuisberg, Leuven, Belgium
227 schema:name Digestive Oncology Unit, University Hospital, Gasthuisberg, Leuven, Belgium
228 rdf:type schema:Organization
229 grid-institutes:grid.5072.0 schema:alternateName Department of Medicine, The Royal Marsden Hospital NHS Foundation Trust, Sutton, Surrey, UK
230 schema:name Department of Medicine, The Royal Marsden Hospital NHS Foundation Trust, Sutton, Surrey, UK
231 rdf:type schema:Organization
232 grid-institutes:grid.51462.34 schema:alternateName Memorial Sloan Kettering Cancer Center, New York City, NY, USA
233 schema:name Memorial Sloan Kettering Cancer Center, New York City, NY, USA
234 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...